Ousia Pharma ApS: Financial statements 2022
CVR: 43055909
Source: annual report 2022, Danish Business Authority
14/02/2022 – 31/12/2022
Ousia Pharma ApS (CVR 43055909) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -644,825 and a net result of DKK -904,151. Equity in the 2022 report amounted to DKK -864,149. The company had 3 employees in the financial year.
- Gross Profit
- DKK -644,825
- Profit/Loss
- DKK -904,151
- Equity
- DKK -864,149
- Total Assets
- DKK 3,279,928
- Employees
- 3
Official annual report
Keep an eye on Ousia Pharma ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
On February 22, 2022, the company changed its name from Ouisa Pharma ApS to Ousia Pharma ApS.
As of February 14, 2022, Christoffer Clemmensen is registered as director of Ousia Pharma ApS.
As of February 14, 2022, Jonas Odgaard Petersen is registered as director of Ousia Pharma ApS.
As of February 14, 2022, Anders Bue Klein is registered as director of Ousia Pharma ApS.
Ousia Pharma ApS was founded on February 14, 2022.
About Ousia Pharma ApS
Ousia Pharma ApS is a Danish company of the type Anpartsselskab based in København N, founded in 2022. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Ouisa Pharma ApS. The management consists of Anders Bue Klein, Christoffer Clemmensen and Jonas Odgaard Petersen. The board consists of Gaurav Gupta (chair), Menelas Nicolas Pangalos, Otello Stampacchia and Ramesh Rajanikant Bhatt. The company is owned by JLSa2 Therapeutics, Inc.. According to the 2025 annual report, the company had an average of 8 employees. In 2025, the company reported a gross profit of DKK -10,204,929 and a net result of DKK -12,777,761 compared with DKK -5,348,579 the year before. Equity in the 2025 report amounted to DKK 11,818,220.